Catch Imagion’s CEO, Bob Proulx, chat with 180 Markets CEO, Greg Lowe, about the future of cancer detection and how our MagSense® medical imaging
Category: Press & Media
Tim Boreham has taken another look at Imagion Biosystems in his latest “Dr. Boreham’s Crucible” column on Biotech Daily. In the column, Tim discusses the
“Imagion says it will prioritize development of its Magsense nanoparticle technology as imaging agents for mainstream clinical magnetic resonance imaging (MRI) scanners. Imagion said that
We recently announced that our MagSense® diagnostic technology has the potential to target prostate cancer tumors, making this the second cancer type the technology has
Our Chairman and CEO Bob Proulx was a recent guest at the Fear and Greed podcast, discussing our pursuit of better, more precise imaging solutions to
Our CEO, Bob Proulx, connected with the Edison Group during their Global Healthcare Open House to discuss in detail, the nanotechnology behind our bio-imaging MagSense technology
Tim Boreham revisits Imagion Biosystems’ potential in this 5-1/2 page article profiling the company and discussing its recent milestones. Read the article here.
As a sponsor of the 2021 Annual VBIC Network Meeting, Imagion Biosystems’ President and CEO, Bob Proulx, gave a presentation on magnetic nanoparticles as imaging
In this video, Chief Development Officer Yalia Jayalakshmi, Ph.D. explains why she joined Imagion Biosystems, the urgency of the company’s mission, and the challenges ahead.